Autopsy report · NCT02992132
Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)
Cause of deathNo reason given
Life of this trial
- Ran for about 1 year 3 months before it stopped.
- 111 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Industry
- Conditions
- Agitation and Aggression in Alzheimer's Disease
- Interventions
- Pimavanserin 34 mg; Pimavanserin 20 mg; Placebo
- Participants
- 111
- Sites
- 56
- Countries
- Chile, France, Spain, United Kingdom, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.